10-Q: Kimberly-Clark Reports Q2 2025 Earnings Amidst Strategic Transformation and IFP Business Divestiture

Kimberly-Clark's second quarter 2025 results show a decline in net sales and profitability from continuing operations, impacted by divestitures, currency fluctuations, and cost inflation, while the company progresses with its 2024 Transformation Initiative and the planned International Family Care and Professional (IFP) business joint venture.

Summary

• Net sales from continuing operations decreased by 1.6% to $4,163 million for the three months ended June 30, 2025, and by 4.0% to $8,217 million for the six months ended June 30, 2025, compared to the prior year.
• Organic sales grew by 3.9% for the three months and 1.2% for the six months, driven by volume gains, partially offset by lower pricing.
• Gross profit declined by 8.7% to $1,456 million for the three months and 9.6% to $2,965 million for the six months, with adjusted gross margin decreasing by 180 basis points and 120 basis points, respectively, primarily due to unfavorable pricing net of cost inflation, including recent tariff impacts.
• Operating profit from continuing operations increased by 9.8% to $592 million for the three months but decreased by 2.5% to $1,223 million for the six months; adjusted operating profit decreased by 2.2% and 4.7% for the respective periods.
• Net income attributable to Kimberly-Clark Corporation was $509 million for the three months and $1,076 million for the six months, down 6.4% and 9.7% respectively.
• Diluted earnings per share from continuing operations were $1.33 for the three months and $2.72 for the six months, a decrease of 1.5% and 8.1% respectively.
• Cash provided by operations for the six months ended June 30, 2025, was $1,097 million, down from $1,459 million in the prior year, primarily due to lower operating profit and higher cash payments for the 2024 Transformation Initiative.
• The 2024 Transformation Initiative incurred pre-tax charges of $122 million for the three months and $199 million for the six months ended June 30, 2025, with cumulative pre-tax charges reaching $656 million.
• The company announced a joint venture with Suzano S.A. for its International Family Care and Professional (IFP) business, with Suzano acquiring a 51% interest for approximately $1.7 billion, expected to close in mid-2026; IFP business results are now reported as discontinued operations.
• Income from discontinued operations, net of income taxes, was $68 million for the three months and $171 million for the six months, a decrease primarily due to $33 million in pre-tax separation costs.

Sentiment

Score: 4

Explanation: The financial results for the quarter and six-month period show a clear decline in key profitability metrics (net sales, gross profit, net income, EPS) from continuing operations compared to the prior year. While organic sales growth is positive, it's overshadowed by the negative impacts of divestitures, currency, and significant transformation costs. Cash flow from operations also decreased. The ongoing transformation and external headwinds (tariffs, inflation) suggest continued pressure, despite some positive long-term strategic moves and favorable tax legislation.

Positives

• Organic sales showed growth of 3.9% for the three months and 1.2% for the six months ended June 30, 2025, driven by volume gains.
• The company achieved gross productivity savings from integrated margin management of approximately $110 million for the three months and $200 million for the six months.
• Marketing, research, and general expenses were lower, partially offsetting declines in adjusted operating profit.
• The effective tax rate for the first half of 2025 benefited from the resolution of certain tax matters.
• A settlement agreement was reached for a qui tam legal matter, which is not expected to materially affect financial position, results of operations, or cash flows.
• The recently enacted One Big Beautiful Bill Act (OBBBA) in the U.S. is expected to have favorable cash tax impacts in the near and medium term.

Negatives

• Net sales from continuing operations decreased by 1.6% for the three months and 4.0% for the six months ended June 30, 2025, compared to the prior year.
• Gross profit and adjusted gross margin declined due to unfavorable pricing net of cost inflation, including recent tariff impacts.
• Adjusted operating profit decreased by 2.2% for the three months and 4.7% for the six months, primarily due to lower net sales and adjusted gross profit.
• Net income attributable to Kimberly-Clark Corporation and diluted earnings per share from continuing operations both decreased year-over-year.
• Cash provided by operations significantly decreased to $1,097 million for the six months ended June 30, 2025, from $1,459 million in the prior year, partly due to higher cash payments for the transformation initiative.
• The effective tax rate increased substantially to 22.6% for the three months and 23.1% for the six months ended June 30, 2025, compared to 13.0% and 18.8% in the prior year.
• Income from discontinued operations decreased due to pre-tax separation costs of $33 million.

Risks

• Changes to U.S. trade policy, including increasing tariffs on imports, are estimated to result in approximately $170 million in incremental costs in 2025, primarily impacting the North America segment.
• The war in Ukraine continues to pose risks, including high input costs, supply chain complexities, reduced consumer demand, restricted access to raw materials and production assets, and restricted access to financial institutions, as well as sanctions and related controls.
• The ability to continue operations in Russia may change as the situation evolves, potentially leading to partial or full impairment of assets.
• The 2024 Transformation Initiative involves significant costs, anticipated to be approximately $1.5 billion pre-tax, with potential for disruptions to business or operations and delays in implementation.
• The company is exposed to financial risks from changes in foreign currency exchange rates, interest rates, and commodity prices.
• The pending IFP Transaction carries risks related to delays or failure to complete, incurrence of significant transaction and separation costs, adverse market reactions, regulatory or legal challenges, and operational disruptions.
• Fluctuations in foreign currency exchange rates and the prices and availability of raw materials could negatively impact financial results.
• Supply chain disruptions, disruptions in capital and credit markets, and counterparty defaults (customers, suppliers, financial institutions) are ongoing risks.
• Failure to realize expected benefits or synergies from acquisition and disposition activity, impairment of goodwill and intangible assets, and changes in customer preferences are potential challenges.
• Severe weather conditions, regional instabilities and hostilities (including the war in Israel), potential competitive pressures on selling prices, and energy costs are external factors that could affect results.

Future Outlook

Full year capital spending is anticipated to be approximately $1.0 billion to $1.2 billion, including incremental spending from the 2024 Transformation Initiative. The 2024 Transformation Initiative is expected to be completed by the end of 2026, with total pre-tax costs of approximately $1.5 billion and expected total pre-tax savings of $3.0 billion in gross productivity and $200 million in selling, general, and administrative expenses. The joint venture for the International Family Care and Professional (IFP) business is expected to close in mid-2026. The recently enacted One Big Beautiful Bill Act (OBBBA) in the U.S. is expected to have favorable cash tax impacts in the near and medium term, though the full impact on consolidated financial statements is still being assessed. The impact of Pillar 2 global minimum corporate tax rules is expected to be immaterial.

Management Comments

• The 2024 Transformation Initiative is designed to sharpen our strategic focus through a new operating model that leverages three synergistic forces: accelerating pioneering innovation, optimizing our margin structure, and wiring our organization for growth.
• Workforce reductions under the 2024 Transformation Initiative are expected to be in the range of 4% to 5% of the organization.
• Our Russia business has represented approximately 1% to 2% of our net global sales, operating profit, and total assets, and our ability to continue operations there may change as the situation evolves.

Industry Context

The consumer staples industry, particularly personal care and tissue products, is facing ongoing challenges from cost inflation, supply chain complexities, and fluctuating foreign currency exchange rates. Kimberly-Clark's results reflect these broader trends, with unfavorable pricing and increased input costs impacting gross margins. The strategic divestiture of the IFP business and the ongoing transformation initiative indicate a proactive approach to streamline operations and improve long-term profitability in a competitive and dynamic global market. The estimated $170 million incremental tariff costs in 2025 highlight the impact of evolving trade policies on multinational consumer goods companies.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A settlement agreement was reached to resolve a qui tam matter related to the former healthcare business, Avanos Medical, Inc., with the payment not expected to materially affect financial position, results of operations, or cash flows.
• The company continues to cooperate in a Department of Justice (DOJ) investigation concerning allegations of potential criminal and civil violations related to the manufacturing, marketing, and sale of surgical gowns by its former healthcare business.

Related Party Transactions

• The company has a supplier finance program managed through two global financial institutions, under which it agrees to pay the financial institutions the stated amount of confirmed invoices from participating suppliers on the invoice due date. As of June 30, 2025, outstanding amounts related to participating suppliers were $1.0 billion, including $213 million related to discontinued operations.

Stakeholder Impact

• Shareholders: Experience a decline in net income and diluted EPS, reflecting current operational challenges and restructuring costs, but also potential long-term benefits from strategic transformation and the IFP joint venture.
• Employees: Workforce reductions are expected in the range of 4% to 5% as part of the 2024 Transformation Initiative, impacting employment.
• Customers: Organic sales growth indicates continued demand for products, but lower pricing suggests competitive pressures or strategic adjustments.
• Suppliers: The supplier finance program continues to be utilized, with $1.0 billion outstanding, indicating ongoing financial arrangements with suppliers.
• Regulatory Authorities: The company is cooperating with a DOJ investigation and has settled a qui tam matter, demonstrating engagement with regulatory compliance.

Next Steps

• Complete the 2024 Transformation Initiative by the end of 2026.
• Finalize the joint venture for the International Family Care and Professional (IFP) business, with an expected closing in mid-2026.
• Continue to assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Cooperate with the Department of Justice (DOJ) investigation related to the former healthcare business's surgical gowns to reach a resolution.

Key Dates

Recommendation

Kimberly-Clark's latest filing presents a mixed financial picture. While organic sales growth is a positive sign of underlying demand for core products, overall net sales, gross profit, and net income have declined year-over-year. This is largely attributable to strategic divestitures, unfavorable currency impacts, and significant costs associated with the ongoing 2024 Transformation Initiative. The company is actively restructuring its portfolio, as evidenced by the IFP joint venture, which is a long-term strategic move. However, the near-term financial performance is being weighed down by these transitional costs and external headwinds like tariffs and inflation. Given the ongoing transformation and the expectation of future savings and favorable tax impacts from recent legislation, a 'hold' recommendation is appropriate. Investors should monitor the execution of the transformation initiative, the successful integration of the IFP joint venture, and the company's ability to mitigate inflationary pressures and tariff impacts to realize the anticipated long-term benefits.

Keywords

Consumer products, Personal care, Tissue products, SEC filing, Quarterly report, Financial results, Transformation initiative, Joint venture, Divestiture, Organic sales, Gross margin, Operating profit, Earnings per share, Cash flow, Tariffs, Inflation, Supply chain, Risk management, Corporate governance